Form Heading

Tag: Inc. (NASDAQ: EYES)

FEATURED NEWS

  • fish covered with necklace and stylish jacketHepion Pharmaceuticals Inc $HEPA: Crazy Amount Of Cash In Hand

    Balance Sheet As Of 2020-12-31

    HEPA shows $40 million in cash and cash equivalents. In my experience, the company has a good amount of cash to conduct additional R&D and increase its marketing efforts. Moreover, Hepion Pharmaceuticals Inc has positive working capital, which market participants will like. It means that HEPA can cover its short-term liabilities when they come due. HEPA's short term debt is less significant than the company's cash and cash equivalents. In my experience, Hepion Pharmaceuticals Inc may not have to worry about any liquidity risk. Moreover, the price to book value is below 1. 5x, which means that HEPA is undervalued. Hepion Pharmaceuticals Inc has $48 million in total assets, and $8 million in total liabilities. In my experience, HEPA is cheap. Additionally, notice that the cash per share is equal to $4, and the stock price is $1. 91. HEPA's debt to equity ratio is below 2x. In short, the debt level appears to be under control. Note that Hepion Pharmaceuticals Inc reports cash and cash equivalents of $40 million, and net debt of $-40 million. With regards to the EV/EBITDA, Hepion Pharmaceuticals Inc trades at 1. I feel that market participants will most likely appreciate this low figure. …
  • CoupleGrubhub Inc. Spikes Up On A Dow Jones report – Check The Goodwill!
    Grubhub Inc., an online and mobile food ordering and delivery marketplace, has hired a financial advisor to consider a sale. Shareholders may not be happy with the announcement. The company’s …
  • Ideanomics Spikes Up
    If you are smart, have a quick look right now at Ideanomics (IDEX). The company is expected to deliver a business presentation. In my opinion, the CEO may provide new information about the new …
  • Expect 40%-50% Reduction In Guidewire’s Share Price
    I believe that Guidewire Software is very overvalued at 10x-12x sales. Using the valuation of peers of 3.9x sales, I would see a reduction of 40%-50% in the share price justifiable. In my opinion, …

Login to your account below

Fill the forms bellow to register

Retrieve your password

Please enter your username or email address to reset your password.